TR201915787A2 - Bosentan monohi̇drat yüklenmi̇ş sivi kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stem ve tablet formülasyonu - Google Patents

Bosentan monohi̇drat yüklenmi̇ş sivi kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stem ve tablet formülasyonu

Info

Publication number
TR201915787A2
TR201915787A2 TR2019/15787A TR201915787A TR201915787A2 TR 201915787 A2 TR201915787 A2 TR 201915787A2 TR 2019/15787 A TR2019/15787 A TR 2019/15787A TR 201915787 A TR201915787 A TR 201915787A TR 201915787 A2 TR201915787 A2 TR 201915787A2
Authority
TR
Turkey
Prior art keywords
emulsive
carrier system
drug carrier
tablet formulation
bosentan monohydrate
Prior art date
Application number
TR2019/15787A
Other languages
English (en)
Inventor
Yilmaz Usta Duygu
Şafak Teksi̇n Zeynep
Original Assignee
Yilmaz Usta Duygu
Zeynep Safak Teksin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yilmaz Usta Duygu, Zeynep Safak Teksin filed Critical Yilmaz Usta Duygu
Priority to TR2019/15787A priority Critical patent/TR201915787A2/tr
Priority to PCT/TR2020/050945 priority patent/WO2021076081A2/en
Priority to EP20876798.8A priority patent/EP4045143A4/en
Publication of TR201915787A2 publication Critical patent/TR201915787A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş bosentan monohidrat içeren sıvı SNEDD sistemin adsorban bir taşıyıcıya adsorbe ettirilmesi (S-SNEDDS) tekniği ile toz halinin katı tablet formuna dönüştürülmesi ile ilgilidir. Sıvı SNEDD sistem belirli oranlarda Gliseril monolinoleat (Maisine®) - Polioksil 40 hidrojene hint yağı (Cremophor®RH 40) - Kaprilokaproil polioksil-8 gliseritlerinden (Labrasol®) oluşmuş, sıvı sistemin katılaştırılmasında adsorban olarak magnezyum aluminometasilikat (Neusilin® US2) kullanılmış ve doğrudan basım yöntemi ile tablet şekline getirilmiştir.
TR2019/15787A 2019-10-14 2019-10-14 Bosentan monohi̇drat yüklenmi̇ş sivi kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stem ve tablet formülasyonu TR201915787A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2019/15787A TR201915787A2 (tr) 2019-10-14 2019-10-14 Bosentan monohi̇drat yüklenmi̇ş sivi kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stem ve tablet formülasyonu
PCT/TR2020/050945 WO2021076081A2 (en) 2019-10-14 2020-10-13 Bosentan monohydrate loaded liquid self nanoemulsifying drug carrier system and tablet formulation
EP20876798.8A EP4045143A4 (en) 2019-10-14 2020-10-13 BOSENTAN MONOHYDRATE LOADED LIQUID SELF-NANOEMULSIFIING DRUG CARRIER SYSTEM AND TABLET FORMULATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2019/15787A TR201915787A2 (tr) 2019-10-14 2019-10-14 Bosentan monohi̇drat yüklenmi̇ş sivi kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stem ve tablet formülasyonu

Publications (1)

Publication Number Publication Date
TR201915787A2 true TR201915787A2 (tr) 2021-04-21

Family

ID=75538003

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/15787A TR201915787A2 (tr) 2019-10-14 2019-10-14 Bosentan monohi̇drat yüklenmi̇ş sivi kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stem ve tablet formülasyonu

Country Status (3)

Country Link
EP (1) EP4045143A4 (tr)
TR (1) TR201915787A2 (tr)
WO (1) WO2021076081A2 (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023240348A1 (en) * 2022-06-14 2023-12-21 Empowerpharm Inc. Pharmaceutical composition for oral administration of cannabinoids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6116905B2 (ja) * 2009-10-23 2017-04-19 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 脂肪酸油混合物の被覆型カプセル剤および錠剤
WO2012139736A1 (en) * 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
WO2015100406A1 (en) * 2013-12-26 2015-07-02 Clarus Therapeutics, Inc. Use of oral pharmaceutical products combining testosterone esters with hypolipidemic agents
WO2016124966A1 (en) * 2014-12-23 2016-08-11 Drug Discovery Laboratory As Inclusion complex between cyclodextrin and non-ionic surfactants

Also Published As

Publication number Publication date
WO2021076081A2 (en) 2021-04-22
EP4045143A2 (en) 2022-08-24
EP4045143A4 (en) 2023-11-08
WO2021076081A3 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
EA200700173A1 (ru) Пористые таблетки в качестве носителей для жидких композиций
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2009044854A1 (ja) 顆粒、錠剤およびそれらの製造方法
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
UA101903C2 (ru) Лекарственное средство на основе дииндолилметана для лечения гиперпластических и воспалительных заболеваний
PH12019500610A1 (en) Controlled release tablet based on polyvinyl alcohol and its manufacturing
WO2006060532A3 (en) Formulations of substituted benzoxazoles
MX2007006565A (es) Formulaciones de benzoxazoles sustituidos.
TR201915787A2 (tr) Bosentan monohi̇drat yüklenmi̇ş sivi kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stem ve tablet formülasyonu
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
WO2014044342A8 (de) Magnesiumhydroxidcarbonat als trägermaterial in wirkstoffhaltigen zubereitungen
PE20050923A1 (es) Composicion solida que comprende un sensibilizador de insulina, un secretagogo de insulina y un ester de acidos grasos
ZA200506992B (en) Fibrate tablet and method for the production thereof
WO2006084475A3 (en) A tablet comprising a fibrate
TW200621305A (en) Pharmaceutical composition
PH12015500469A1 (en) High dose extended-release potassium citrate wax matrix tablet
CY1107277T1 (el) Βενζισοξαζολες
EA201800197A1 (ru) Способ получения фармацевтической композиции в форме таблеток, содержащих в качестве действующего вещества абиратерона ацетат, и фармацевтическая композиция
EA201000179A1 (ru) Способ изготовления прессованного фармацевтического препарата, содержащего тиболон
TR201714150A1 (tr) Kolekalsiferol İçeren Efervesan Tablet Formunda Bir Farmasötik Formülasyon.
TR202018841A2 (tr) Uzun zi̇nci̇rli̇ mono ve di̇gli̇seri̇t karişimlari i̇le hazirlanan bosentan monohi̇drat yüklü kendi̇li̇ği̇nden nanoemülsi̇fi̇ye i̇laç taşiyici si̇stemleri̇n (snedds) formülasyonu
RU2010138668A (ru) Спрессованные таблетки
UA102844U (uk) Таблетка, що містить тетрагідрат dl-гідроаспарагінату магнію, напівгідрат dl-аспарагінату калію та сухий екстракт глоду криваво-червоного
UA111358C2 (uk) Тверда лікарська форма препарату седативної та снодійної дії